Sermorelin vs Tesamorelin: Comparing Two GHRH Analogue Peptides
Research Guide

Sermorelin vs Tesamorelin: Comparing Two GHRH Analogue Peptides

Sermorelin and Tesamorelin are both analogues of growth hormone-releasing hormone, and both are studied through the same receptor. The difference between them is a matter of sequence length and molecular stability – which turns out to matter a great deal in experimental terms, because it changes how long each molecule survives in a biological matrix rather than what it does when it arrives.

The shared starting point

Endogenous GHRH is a 44-amino-acid peptide produced in the hypothalamus. Its biological activity resides largely in the N-terminal region, which is why analogue design has concentrated there. The GHRH receptor is a class B G-protein-coupled receptor; in laboratory models its activation is read out through cyclic AMP signalling in somatotroph cells, which gives researchers a well-characterised, receptor-specific endpoint for comparing analogues.

Sermorelin

Sermorelin corresponds to GHRH(1-29) – the first 29 amino acids of the parent hormone. It is the shortest fragment that retains the parent molecule’s receptor activity in published models, which is why it became a standard research tool for GHRH receptor work. Because it carries no protective modification, it is also a useful reference compound: whatever stability a modified analogue shows is measured against the unmodified fragment.

Tesamorelin

Tesamorelin is also based on GHRH(1-44) but carries a trans-3-hexenoyl group attached at the N-terminus. That modification is the entire point of the molecule: the N-terminus is where dipeptidyl peptidase-4 (DPP-4) cleaves GHRH, and the added group is associated in published work with substantially greater resistance to that degradation.

Why the N-terminus matters

DPP-4 recognises peptides with alanine or proline in the second position and removes the first two residues. GHRH begins with tyrosine followed by alanine, so it is a natural substrate: cleavage produces GHRH(3-44), a fragment that has lost most of its activity at the receptor. In circulation the native hormone persists for only a few minutes, and the same vulnerability applies to any unmodified fragment that preserves the Tyr-Ala N-terminus, Sermorelin included.

Acylating the N-terminus, as in Tesamorelin, obstructs the enzyme without changing the residues that contact the receptor. Published characterisation describes the result as a molecule with the same receptor target and a materially longer survival time in enzyme-containing matrices. The two compounds therefore differ along one well-defined axis, and that is what makes the pair a clean experimental comparison.

Side by side

Sermorelin Tesamorelin
Basis GHRH(1-29) GHRH(1-44) analogue
Modification None – truncated fragment N-terminal trans-3-hexenoyl group
DPP-4 susceptibility Higher Lower
Receptor GHRH receptor GHRH receptor
Form supplied Lyophilized powder Lyophilized powder

Why stability changes the experiment

Because both act at the same receptor, the mechanistic question is not which pathway they engage but how long the molecule persists to engage it. A study comparing the two is in practice studying the effect of enzymatic stability while holding the receptor target constant – a fairly clean design, and one reason the pair appears together in the literature.

That has consequences for how results are read. In a cell-based assay with no DPP-4 present, the two analogues would be expected to behave much more alike than they do in serum-containing systems or whole-animal models, where enzymatic degradation is in play. A difference that appears in one setting and not the other points to stability rather than receptor pharmacology, and a design that includes both settings can separate the two explanations.

This also distinguishes both from the ghrelin-receptor secretagogues. Ipamorelin and the CJC-1295 and Ipamorelin preparation act through the growth hormone secretagogue receptor, a different route entirely. Comparing a GHRH analogue with a ghrelin-receptor agonist compares two pathways; comparing Sermorelin with Tesamorelin compares two molecules on one pathway.

Practical research notes

Both compounds are characterised the same way: HPLC establishes purity as the percentage of the sample that elutes as the main peak, and mass spectrometry confirms identity by matching the observed mass to the expected molecule. The two are easy to tell apart analytically, since Tesamorelin is both longer and carries the additional acyl group, so a certificate of analysis for one cannot be mistaken for the other.

Nomenclature deserves a note. Sermorelin is sometimes listed as GRF(1-29), and modified GRF(1-29) – the no-DAC form of CJC-1295 – is a different molecule again, with four amino-acid substitutions. Confirming which sequence a certificate of analysis describes avoids a common source of confusion when comparing results across papers.

Both are available as Sermorelin 10mg and Tesamorelin 10mg, and the research library collects our other guides to GHRH-pathway compounds.

Frequently Asked Questions

Do Sermorelin and Tesamorelin act on the same receptor?

Yes. Both are GHRH analogues acting at the GHRH receptor. They differ in sequence basis and in resistance to enzymatic degradation, not in target.

What does the trans-3-hexenoyl group on Tesamorelin do?

It is attached at the N-terminus, which is the region DPP-4 cleaves. Published work associates the modification with greater resistance to that degradation.

Why is Sermorelin only 29 amino acids?

GHRH(1-29) is the shortest N-terminal fragment shown in published models to retain the parent hormone’s receptor activity.

How do these differ from Ipamorelin?

Ipamorelin acts at the growth hormone secretagogue (ghrelin) receptor, a separate pathway. Sermorelin and Tesamorelin act at the GHRH receptor.

For Research Use Only

All compounds discussed in this article are supplied strictly for laboratory research purposes. They are not drugs, foods, cosmetics, or dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. This article summarises published preclinical literature for educational purposes and does not constitute guidance on use of any kind.

All Santa Cruz Peptides products are supplied strictly for laboratory and research use only. They are not for human or veterinary use, diagnosis, treatment, or consumption.

Research material: Tesamorelin in every vial size (5mg–20mg)

Cart0
×

Research updates from Santa Cruz Peptides

New compounds, restocks and research guides — straight to your inbox.

For laboratory and research use only. Unsubscribe anytime.
Free Shipping On All Orders!